Vanda Pharmaceuticals (VNDA) Adopts Limited Duration Stockholder Rights Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vanda Pharmaceuticals (VNDA) Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
April 17, 2024 9:07 AM EDTVanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that, since March 2024, it received several unsolicited proposals from Future Pak, LLC ("Future Pak"), to acquire all of the outstanding shares of Vanda (the "Conditional Proposals"). The most recent... More
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals (VNDA) for $7.25-$7.75/sh Cash
April 17, 2024 6:31 AM EDTFuture Pak LLC (Future Pak) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals, Inc. (Vanda) (NASDAQ: VNDA), and confirms that its most recent proposal to acquire Vanda for cash consideration of $7.25 to $7.75 per share remains open for Vanda and its Board of Directors to consider.
The current proposal implies a... More
